People: Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

27 May 2020
Change (% chg)

$0.59 (+1.12%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Hirsch, Andrew 

Mr. Andrew Hirsch serves as Chief Financial Officer and Head of Corporate Development of the Company. He has more than 20 years of experience in a range of strategic and operating roles in the biotech sector, most recently having served as president and chief executive officer of BIND Therapeutics, Inc., a biotechnology company, from March 2015 until August 2016. Prior to being named president and chief executive officer at BIND, Mr. Hirsch held several other leadership positions at the company, including chief operating officer from February 2014 to March 2015, and chief financial officer from July 2012 to March 2015. Prior to joining BIND, Mr. Hirsch was chief financial officer at Avila Therapeutics, Inc., a biotechnology company, from June 2011 until its acquisition by Celgene Corporation in March 2012. From 2002 to 2011, Mr. Hirsch held roles of increasing responsibility at Biogen Idec, including vice president of Corporate Strategy and M&A and program executive for the Tecfidera development team. He holds an M.B.A. from the Tuck School at Dartmouth College and a B.A. in Economics from the University of Pennsylvania.

Basic Compensation

Total Annual Compensation, USD 500,476
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 3,748,360
Fiscal Year Total, USD 4,248,830

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Schenkein


Jacqualyn Fouse


Andrew Hirsch


Bruce Car


Jonathan Biller


Christopher Bowden

As Of  31 Dec 2019